No retraction, correction or concern found when last checked on Nov 2, 2026.

YTHDF2 inhibition potentiates radiotherapy antitumor efficacy

Liangliang Wang, Xiaoyang Dou, Shijie Chen and 19 more (opens in a new tab)

Cancer Cell · 2023

doi:10.1016/j.ccell.2023.04.019 (opens in a new tab)

Read free

References 92

1.
Liauw SL, Connell PP, and Weichselbaum RR (2013 ). New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology. Science Translational Medicine 5, 173sr2.
Not in our library10.1126/scitranslmed.3005148 (opens in a new tab)
2.
Weichselbaum RR, Liang H, Deng LF, and Fu YX (2017 ). Radiotherapy and immunotherapy: a beneficial liaison? Nature Reviews Clinical Oncology 14, 365–379.
Not in our library10.1038/nrclinonc.2016.211 (opens in a new tab)
3.
Cancer Stem Cells and Radioresistance: DNA Repair and Beyond · 2019
No notice
4.
Fridman WH, Zitvogel L, Sautes-Fridman C, and Kroemer G (2017 ). The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14, 717–734.
Not in our library10.1038/nrclinonc.2017.101 (opens in a new tab)
5.
Brandmaier A, and Formenti SC (2020 ). The Impact of Radiation Therapy on Innate and Adaptive Tumor Immunity. Semin Radiat Oncol 30, 139–144.
Not in our library10.1016/j.semradonc.2019.12.005 (opens in a new tab)
6.
Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, and Auh SL (2011 ). The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71, 2488–2496.
Not in our library10.1158/0008-5472.can-10-2820 (opens in a new tab)
7.
Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, (2018 ). Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24, 1845–1851.
Not in our library10.1038/s41591-018-0232-2 (opens in a new tab)
8.
Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, (2009 ). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589–595.
Not in our library10.1182/blood-2009-02-206870 (opens in a new tab)
9.
Searle EJ, Telfer BA, Mukherjee D, Forster DM, Davies BR, Williams KJ, Stratford IJ, and Illidge TM (2017 ). Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment. EMBO Mol Med 9, 1646–1659.
Not in our library10.15252/emmm.201707767 (opens in a new tab)
10.
Pointer KB, Pitroda SP, and Weichselbaum RR (2022 ). Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer 8, 9–20.
Not in our library10.1016/j.trecan.2021.10.003 (opens in a new tab)
11.
Turchan WT, Pitroda SP, and Weichselbaum RR (2021 ). Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res 27, 5188–5194.
Not in our library10.1158/1078-0432.ccr-21-0145 (opens in a new tab)
12.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, (2017 ). Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 377, 1919–1929.
Not in our library10.1056/nejmoa1709937 (opens in a new tab)
13.
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lievre A, (2021 ). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 384, 1191–1203.
Not in our library10.1056/nejmoa2032125 (opens in a new tab)
14.
Bang A, and Schoenfeld JD (2019 ). Immunotherapy and radiotherapy for metastatic cancers. Ann Palliat Med 8, 312–325.
Not in our library10.21037/apm.2018.07.10 (opens in a new tab)
15.
Colton M, Cheadle EJ, Honeychurch J, and Illidge TM (2020 ). Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiat Oncol 15, 254.
Not in our library10.1186/s13014-020-01678-1 (opens in a new tab)
16.
Gabrilovich DI, and Nagaraj S (2009 ). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9, 162–174.
Not in our library10.1038/nri2506 (opens in a new tab)
17.
Zhao JL, Ye YC, Gao CC, Wang L, Ren KX, Jiang R, Hu SJ, Liang SQ, Bai J, Liang JL, (2022 ). Notch-mediated lactate metabolism regulates MDSC development through the Hes1/MCT2/c-Jun axis. Cell Rep 38, 110451.
Not in our library10.1016/j.celrep.2022.110451 (opens in a new tab)
18.
Engblom C, Pfirschke C, and Pittet MJ (2016 ). The role of myeloid cells in cancer therapies. Nat Rev Cancer 16, 447–462.
Not in our library10.1038/nrc.2016.54 (opens in a new tab)
19.
Jimenez-Cortegana C, Galassi C, Klapp V, Gabrilovich DI, and Galluzzi L (2022 ). Myeloid-Derived Suppressor Cells and Radiotherapy. Cancer Immunol Res 10, 545–557.
Not in our library10.1158/2326-6066.cir-21-1105 (opens in a new tab)
20.
Barker HE, Paget JTE, Khan AA, and Harrington KJ (2015 ). The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nature Reviews Cancer 15, 409–425.
Not in our library10.1038/nrc3958 (opens in a new tab)
21.
Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng WG, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, (2015 ). The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine 21, 938–945.
Not in our library10.1038/nm.3909 (opens in a new tab)
22.
Haughey CM, Mukherjee D, Steele RE, Popple A, Dura-Perez L, Pickard A, Patel M, Jain S, Mullan PB, Williams R, (2020 ). Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. Cancers (Basel) 12, 2804.
Not in our library10.3390/cancers12102804 (opens in a new tab)
23.
Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, and Reiter RE (2021 ). High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. Clin Cancer Res 27, 1505–1515.
Not in our library10.1158/1078-0432.ccr-20-2293 (opens in a new tab)
24.
Oweida AJ, Mueller AC, Piper M, Milner D, Van Court B, Bhatia S, Phan A, Bickett T, Jordan K, Proia T, (2021 ). Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. Cancer Immunol Immunother 70, 989–1000.
Not in our library10.1007/s00262-020-02701-w (opens in a new tab)
25.
Ghosh S, Huang J, Inkman M, Zhang J, Thotala S, Tikhonova E, Miheecheva N, Frenkel F, Ataullakhanov R, Wang X, (2023 ). Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. Sci Transl Med 15, eabn6758.
Not in our library10.1126/scitranslmed.abn6758 (opens in a new tab)
26.
Host STING-dependent MDSC mobilization drives extrinsic radiation resistance · 2017
No notice
27.
Fu SY, Chen FH, Wang CC, Yu CF, Chiang CS, and Hong JH (2021 ). Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment. Radiat Oncol Biol Phys 109, 1547–1558.
Not in our library10.1016/j.ijrobp.2020.11.004 (opens in a new tab)
28.
Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, (2016 ). Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer 115, 252–260.
Not in our library10.1038/bjc.2016.166 (opens in a new tab)
29.
Tsai MS, Chen WC, Lai CH, Chen YY, and Chen MF (2017 ). Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer. Oral Oncol 73, 88–96.
Not in our library10.1016/j.oraloncology.2017.08.007 (opens in a new tab)
30.
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients · 2017
No notice
31.
Talebian Yazdi M, Schinkelshoek MS, Loof NM, Taube C, Hiemstra PS, Welters MJ, and van der Burg SH (2016 ). Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer. Oncoimmunology 5, e1255393.
Not in our library10.1080/2162402x.2016.1255393 (opens in a new tab)
32.
Wang D, An G, Xie S, Yao Y, and Feng G (2016 ). The clinical and prognostic significance of CD14(+)HLA-DR(−/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Tumour Biol 37, 10427–10433.
Not in our library10.1007/s13277-016-4916-2 (opens in a new tab)
33.
Tsai MS, Chen WC, Lu CH, and Chen MF (2019 ). The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling. Oral Oncol 91, 47–55.
Not in our library10.1016/j.oraloncology.2019.02.027 (opens in a new tab)
34.
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer · 2020
No notice
35.
Ko JS, Zea AH, Rin BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, (2009 ). Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients. Clinical Cancer Research 15, 2148–2157.
Not in our library10.1158/1078-0432.ccr-08-1332 (opens in a new tab)
36.
Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, (2016 ). Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. Cancer Cell 29, 587–601.
Not in our library10.1016/j.ccell.2016.03.005 (opens in a new tab)
37.
Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, Goodman S, Gourin CG, Ha PK, Fakhry C, (2015 ). Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 21, 30–38.
Not in our library10.1158/1078-0432.ccr-14-1716 (opens in a new tab)
38.
Iclozan C, Antonia S, Chiappori A, Chen DT, and Gabrilovich D (2013 ). Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunology Immunotherapy 62, 909–918.
Not in our library10.1007/s00262-013-1396-8 (opens in a new tab)
39.
Frye M, Harada BT, Behm M, and He C (2018 ). RNA modifications modulate gene expression during development. Science 361, 1346–1349.
Not in our library10.1126/science.aau1646 (opens in a new tab)
40.
Wang X, and He C (2014 ). Dynamic RNA Modifications in Posttranscriptional Regulation. Molecular Cell 56, 5–12.
Not in our library10.1016/j.molcel.2014.09.001 (opens in a new tab)
41.
Roundtree IA, Evans ME, Pan T, and He C (2017 ). Dynamic RNA Modifications in Gene Expression Regulation. Cell 169, 1187–1200.
Not in our library10.1016/j.cell.2017.05.045 (opens in a new tab)
42.
Shi HL, Wang X, Lu ZK, Zhao BXS, Ma HH, Hsu PJ, Liu C, and He C (2017 ). YTHDF3 facilitates translation and decay of N-6-methyladenosine-modified RNA. Cell Research 27, 315–328.
Not in our library10.1038/cr.2017.15 (opens in a new tab)
43.
Wang X, Lu ZK, Gomez A, Hon GC, Yue YN, Han DL, Fu Y, Parisien M, Dai Q, Jia GF, (2014 ). N-6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505, 117–120.
Not in our library10.1038/nature12730 (opens in a new tab)
44.
Wang X, Zhao BS, Roundtree IA, Lu ZK, Han DL, Ma HH, Weng XC, Chen K, Shi HL, and He C (2015 ). N-6-methyladenosine Modulates Messenger RNA Translation Efficiency. Cell 161, 1388–1399.
Not in our library10.1016/j.cell.2015.05.014 (opens in a new tab)
45.
Dixit D, Prager BC, Gimple RC, Poh HX, Wang Y, Wu QL, Qiu ZX, Kidwell RL, Kim LJY, Xie Q, (2021 ). The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discovery 11, 480–499.
Not in our library10.1158/2159-8290.cd-20-0331 (opens in a new tab)
46.
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma · 2019
Corrected
47.
Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, Mapperley C, Lawson H, Wotherspoon DA, Sepulveda C, (2019 ). Targeting the RNA m(6)A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia. Cell Stem Cell 25, 137–148.e6.
Not in our library10.1016/j.stem.2019.03.021 (opens in a new tab)
48.
METTL3/YTHDF2 m 6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer · 2020
No notice
49.
Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, Chen Y, Sulman EP, Xie K, Bogler O, (2017 ). m(6)A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell 31, 591–606 e596.
Not in our library10.1016/j.ccell.2017.02.013 (opens in a new tab)
50.
Han DL, Liu J, Chen CY, Dong LH, Liu Y, Chang RB, Huang XN, Liu YY, Wang JY, Dougherty U, (2019 ). Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 566, 270–274.
Not in our library10.1038/s41586-019-0916-x (opens in a new tab)
51.
Fei Q, Zou Z, Roundtree IA, Sun HL, and He C (2020 ). YTHDF2 promotes mitotic entry and is regulated by cell cycle mediators. PLoS Biol 18, e3000664.
Not in our library10.1371/journal.pbio.3000664 (opens in a new tab)
52.
N6-methyladenosine modification and the YTHDF2 reader protein play cell type specific roles in lytic viral gene expression during Kaposi's sarcoma-associated herpesvirus infection · 2018
No notice
53.
Li Z, Qian P, Shao W, Shi H, He XC, Gogol M, Yu Z, Wang Y, Qi M, Zhu Y, (2018 ). Suppression of m(6)A reader Ythdf2 promotes hematopoietic stem cell expansion. Cell Res 28, 904–917.
Not in our library10.1038/s41422-018-0072-0 (opens in a new tab)
54.
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function · 2020
No notice
55.
Wang H, Zuo H, Liu J, Wen F, Gao Y, Zhu X, Liu B, Xiao F, Wang W, Huang G, (2018 ). Loss of YTHDF2-mediated m(6)A-dependent mRNA clearance facilitates hematopoietic stem cell regeneration. Cell Res 28, 1035–1038.
Not in our library10.1038/s41422-018-0082-y (opens in a new tab)
56.
Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, (2018 ). Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36, 1611–1618.
Not in our library10.1200/jco.2017.76.2229 (opens in a new tab)
57.
Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, (2022 ). A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol 17, 130–140.
Not in our library10.1016/j.jtho.2021.08.019 (opens in a new tab)
58.
Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q, Rath JA, Nee K, Hernandez G, Evans K, Torosian L, (2020 ). Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol 5, eaay6017.
Not in our library10.1126/sciimmunol.aay6017 (opens in a new tab)
59.
Ichim CV, Atkins HL, Iscove NN, and Wells RA (2011 ). Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy. Leukemia 25, 1687–1696.
Not in our library10.1038/leu.2011.137 (opens in a new tab)
60.
Wynn TA (2013 ). Myeloid-cell differentiation redefined in cancer. Nat Immunol 14, 197–199.
Not in our library10.1038/ni.2539 (opens in a new tab)
61.
Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, and Kufe D (1991 ). Ionizing-Radiation Induces Expression And Binding-Activity Of The Nuclear Factor-Kappa-B. Journal of Clinical Investigation 88, 691–695.
Not in our library10.1172/jci115354 (opens in a new tab)
62.
Erstad DJ, and Cusack JC (2013 ). Targeting the NF-kappa B Pathway in Cancer Therapy. Surgical Oncology Clinics of North America 22, 705–746.
Not in our library10.1016/j.soc.2013.06.011 (opens in a new tab)
63.
Hou YZ, Liang H, Rao EY, Zheng WX, Huang XN, Deng LF, Zhang Y, Yu XS, Xu M, Mauceri H, (2018 ). Non-canonical NF-kappa B Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. Immunity 49, 490–503.
Not in our library10.1016/j.immuni.2018.07.008 (opens in a new tab)
64.
Oeckinghaus A, and Ghosh S (2009 ). The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1, a000034.
Not in our library10.1101/cshperspect.a000034 (opens in a new tab)
65.
Heinz LX, Baumann CL, Koberlin MS, Snijder B, Gawish R, Shui G, Sharif O, Aspalter IM, Muller AC, Kandasamy RK, (2015 ). The Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity. Cell Rep 11, 1919–1928.
Not in our library10.1016/j.celrep.2015.05.006 (opens in a new tab)
66.
Jung TW, Pyun DH, Kim TJ, Lee HJ, Park ES, Abd El-Aty AM, Hwang EJ, Shin YK, and Jeong JH (2021 ). Meteorin-like protein (METRNL)/IL-41 improves LPS-induced inflammatory responses via AMPK or PPARdelta-mediated signaling pathways. Adv Med Sci 66, 155–161.
Not in our library10.1016/j.advms.2021.01.007 (opens in a new tab)
67.
Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, (2008 ). TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 133, 415–426.
Not in our library10.1016/j.cell.2008.03.026 (opens in a new tab)
68.
Takenaka MC, Araujo LP, Maricato JT, Nascimento VM, Guereschi MG, Rezende RM, Quintana FJ, and Basso AS (2016 ). Norepinephrine Controls Effector T Cell Differentiation through beta2-Adrenergic Receptor-Mediated Inhibition of NF-kappaB and AP-1 in Dendritic Cells. J Immunol 196, 637–644.
Not in our library10.4049/jimmunol.1501206 (opens in a new tab)
69.
Yoshimura A, Nishinakamura H, Matsumura Y, and Hanada T (2005 ). Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther 7, 100–110.
Not in our library10.1186/ar1741 (opens in a new tab)
70.
Condamine T, Mastio J, and Gabrilovich DI (2015 ). Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol 98, 913–922.
Not in our library10.1189/jlb.4ri0515-204r (opens in a new tab)
71.
Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, Tomonaga M, Yamamoto N, and Fujii M (2002 ). Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100, 1828–1834.
Not in our library10.1182/blood-2002-01-0151 (opens in a new tab)
72.
Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, and He C (2017 ). YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res 27, 315–328.
Not in our library10.1038/cr.2017.15 (opens in a new tab)
73.
Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, Sun HY, Zhu Q, Baidya P, Wang X, (2017 ). Cytoplasmic m(6)A reader YTHDF3 promotes mRNA translation. Cell Res 27, 444–447.
Not in our library10.1038/cr.2017.10 (opens in a new tab)
74.
Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation · 2020
Not checked
75.
Zheng SL, Li ZY, Song J, Liu JM, and Miao CY (2016 ). Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin 37, 571–579.
Not in our library10.1038/aps.2016.9 (opens in a new tab)
76.
Schottelius AJ, Mayo MW, Sartor RB, and Baldwin AS Jr. (1999 ). Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274, 31868–74.
Not in our library10.1074/jbc.274.45.31868 (opens in a new tab)
77.
Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, (2021 ). Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593, 597–601.
Not in our library10.1038/s41586-021-03536-w (opens in a new tab)
78.
Nguyen HCB, Adlanmerini M, Hauck AK, Lazar MA (2020 ). Dichotomous engagement of HDAC3 activity governs inflammatory responses. Nature. 584, 286–290.
Not in our library10.1038/s41586-020-2576-2 (opens in a new tab)
79.
Ythdf2-mediated m6A mRNA clearance modulates neural development in mice · 2018
No notice
80.
Zhu T, Roundtree IA, Wang P, Wang X, Wang L, Sun C, Tian Y, Li J, He C, Xu Y (2014 ). Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N6-methyladenosine. Cell Res. 24, 1493–6.
Not in our library10.1038/cr.2014.152 (opens in a new tab)
81.
McGinnis CS, Murrow LM, Gartner ZJ (2019 ) DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 8, 329–337.
Not in our library10.1016/j.cels.2019.03.003 (opens in a new tab)
82.
Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM 3rd, Hao Y, Stoeckius M, Smibert P, Satija R (2019 ). Comprehensive Integration of Single-Cell Data. Cell. 177, 1888–1902.
Not in our library10.1016/j.cell.2019.05.031 (opens in a new tab)
83.
scClassify: sample size estimation and multiscale classification of cells using single and multiple reference · 2020
No notice
84.
Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O’Brien SA, He Y, Wang L, Zhang Q, Kim A, (2020 ). Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. Cell. 181, 442–459.
Not in our library10.1016/j.cell.2020.03.048 (opens in a new tab)
85.
Trimmomatic: a flexible trimmer for Illumina sequence data · 2014
No notice
86.
Kim D, Paggi JM, Park C, Bennett C, and Salzberg SL (2019 ). Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol. 37, 907–915.
Not in our library10.1038/s41587-019-0201-4 (opens in a new tab)
87.
Twelve years of SAMtools and BCFtools · 2021
No notice
88.
Model-based Analysis of ChIP-Seq (MACS) · 2008
No notice
89.
HTSeq—a Python framework to work with high-throughput sequencing data · 2014
No notice
90.
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · 2014
No notice
91.
Huang da. W., Sherman BT, and Lempicki RA (2009 ). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13.
Not in our library10.1093/nar/gkn923 (opens in a new tab)
92.
Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, (2020 ).Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol 38, 675–678.
Not in our library10.1038/s41587-020-0546-8 (opens in a new tab)

Cited by papers we hold 3

Phosphorus-32 microspheres: A dual-modality transarterial radioembolization approach for hepatocellular carcinoma therapy and Anti-PD1 immunotherapy potentiation · 2025
Not checked
The role of RNA methylation in tumor immunity and its potential in immunotherapy · 2024
No notice
Epigenetics-targeted drugs: current paradigms and future challenges · 2024
No notice

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.